RNS Number : 6706Z AstraZeneca PLC 06 March 2025 6 March 2025 Transactions by Persons Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that, on 4 and 5 March 2025, awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP). The AZDBP award was granted on 4 March 2022, following the deferral of a portion of each PDMR's annual bonus in respect of 2021 performance into Ordinary Shares, and vested on completion of the three-year holding period. The Ordinary Shares that vested on 5 March 2025 relate to the reinvestment of certain dividends accrued during the deferral period of the AZDBP award. Following the reinvestment of dividends accrued during the deferral period of the AZDBP award, and the withholding of shares to satisfy certain tax obligations arising on vesting, the PDMRs' beneficial interests in Ordinary Shares changed as detailed in the table below: For tax purposes, the fair market value of an Ordinary Share at vest of the AZDBP award was 11,904 pence, being the closing price on the last trading day preceding the vesting. Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018). AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca Contacts For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here. Adrian Kemp Company Secretary AstraZeneca PLC This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END DSHUNUARVVUORAR